STOCK TITAN

Vivani Medical: 0.79% weight loss in implant trial

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Vivani Medical, Inc. (VANI) reported top-line results from its four-week Phase 1 SLIM-1 trial of NPM-139, an investigational semaglutide implant, compared with weekly Wegovy in 10 participants per group. No treatment-related adverse events were reported in the NPM-139 group; five of 10 Wegovy participants had treatment-related gastrointestinal events. No serious adverse events occurred in either group. Observed weight loss was 0.79% with NPM-139 and 0.82% with Wegovy. Maximum semaglutide levels after a single NPM-139 administration were measured at approximately 16 days, versus approximately 2.4 days after the first Wegovy injection.

For the third quarter of 2026, net loss was $7.25 million, versus $6.53 million in the prior-year quarter. Cash, cash equivalents and restricted cash totaled $15.5 million as of September 30, 2026, compared with $20.8 million as of June 30, 2026.

Vivani plans to advance NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027, and to explore development in GLP-1-naïve patients. The Cortigent merger remains subject to final regulatory approval; ClearOne is pursuing financing aimed at raising $10 million to $15 million concurrently with the merger’s closing.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointQuarterly net loss widened to $7.25 million from $6.53 million a year earlier.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and restricted cash $15.5 million As of September 30, 2026; compared with $20.8 million as of June 30, 2026
Net loss $7.25 million Three months ended September 30, 2026; $6.53 million in the prior-year quarter
Research and development expense, net of grants $5.021 million Three months ended September 30, 2026; $4.519 million in 2025
General and administrative expense, net of grants $2.511 million Three months ended September 30, 2026; $2.206 million in 2025
Treatment-related adverse events 0 of 10 NPM-139 participants; 5 of 10 Wegovy participants SLIM-1 Phase 1 trial
Time to maximum semaglutide levels Approximately 16 days for NPM-139; approximately 2.4 days for Wegovy After a single NPM-139 administration and after the first Wegovy injection, respectively
Observed weight loss 0.79% with NPM-139; 0.82% with Wegovy Four-week SLIM-1 trial
open-label medical
"SLIM-1 is an open-label, active-controlled clinical trial"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
active-controlled medical
"an open-label, active-controlled clinical trial"
An active-controlled study is a trial in which the new treatment is compared against an existing, approved treatment instead of a placebo. For investors, this matters because results show how the new product stacks up against the current standard—like testing a new phone by comparing it to a popular model rather than to no phone—so positive results can indicate real competitive advantage and clearer market value.
pharmacokinetic profile medical
"evaluate the safety, tolerability and pharmacokinetic profile"
The pharmacokinetic profile describes how a drug moves through the body over time, including how quickly it is absorbed, how it spreads, and how it is eventually eliminated. For investors, understanding this profile helps gauge the drug’s effectiveness, safety, and the appropriate dosing schedule, which can influence a company’s potential success and market value. It provides insight into how a medication behaves, impacting its overall commercial viability.
dose-ranging medical
"Phase 2 dose-ranging weight maintenance trial"
A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.
GLP-1-naïve medical
"clinical development of NPM-139 in GLP-1-naïve patients"
Net loss $7.25 million $6.53 million in the three months ended September 30, 2025
Research and development expense, net of grants $5.021 million $4.519 million in the three months ended September 30, 2025
General and administrative expense, net of grants $2.511 million $2.206 million in the three months ended September 30, 2025
Other income, net $0.282 million $0.195 million in the three months ended September 30, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were VANI’s SLIM-1 weight-loss results?

Observed weight loss over the four-week trial was 0.79% in the NPM-139 group and 0.82% in the Wegovy group. Each group included 10 participants.

When is Vivani’s NPM-139 Phase 2 study expected to begin?

Vivani plans to advance NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027. The company also plans to explore potential clinical development in GLP-1-naïve patients.

What dose of Wegovy was used in VANI’s SLIM-1 trial?

The control group received the starting dose of Wegovy: 0.25 mg of semaglutide by weekly injection. The trial lasted four weeks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001266806 false00012668062026-11-112026-11-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 11, 2026

 

 

Vivani Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36747

 

02-0692322

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1350 S. Loop Road

Alameda, California

 

94502

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (415) 506-8462

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VANI

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 



Item 2.02 Results of Operations and Financial Condition.

 

On November 11, 2026, Vivani Medical, Inc. (the “Company”) issued a press release titled “Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update” which is attached to this Current Report on Form 8-K (this “Current Report”) as Exhibit 99.1 and is incorporated by reference herein.

 

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.  

 

Item 7.01. Regulation FD Disclosure

 

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached to this Current Report as Exhibit 99.2 and are incorporated by reference herein. The Company is also posting to the “Investors” portion of its website a copy of its current corporate slide presentation. The slides speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current Report, the Company specifically disclaims any obligation to do so.

 

The information contained in this Item 7.01 and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

 

Item 8.01 Other Events.

 

 On November 12, 2026, the Company issued a press release titled “Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects,” which is attached to this Current Report as Exhibit 99.3 and is incorporated by reference.

 

SLIM-1 was a four-week, open-label, active-controlled Phase 1 clinical trial conducted at a single study center in Australia to evaluate the safety, tolerability and pharmacokinetic profile of low-dose NPM-139, the Company’s investigational semaglutide implant, in otherwise healthy overweight or obese participants. Ten participants received NPM-139 and ten participants received the starting dose of Wegovy (0.25 mg of semaglutide administered by weekly injection). Changes in body weight were also measured. NPM-139 is a subdermal implant utilizing the Company’s proprietary NanoPortal™ technology and is being designed for once- or twice-yearly administration for chronic weight management.

 

SLIM-1 Top-Line Results

 

No adverse events were reported as treatment related in the NPM-139 group, compared with treatment-related adverse events in five of ten participants in the Wegovy group, all of which were gastrointestinal. No serious adverse events were reported in either group.

 

The pharmacokinetic results showed no rapid increases in drug exposure with NPM-139, with maximum semaglutide levels following a single administration measured at approximately 16 days, compared with approximately 2.4 days following the first weekly Wegovy injection. Over the four-week trial, observed weight loss was 0.79% in the NPM-139 group and 0.82% in the Wegovy group.

 

NPM-139 Development Plans

 

Based on the top-line results, the Company plans to advance NPM-139 toward a Phase 2 dose-ranging weight maintenance trial, which is anticipated to begin in 2027. The Company also plans to explore the potential for clinical development of NPM-139 in GLP-1-naïve patients based on the tolerability profile observed in SLIM-1.

 



 

Forward-Looking Statements

 

This Current Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical fact, and may include statements regarding the potential of NPM-139 for chronic weight management and once- or twice-yearly administration, the Company’s plans to advance NPM-139 toward a Phase 2 dose-ranging weight maintenance trial and the anticipated timing thereof, and the potential for clinical development in GLP-1-naïve patients. These statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, risks relating to the Company’s development and commercialization of product candidates, unexpected costs or delays, and changes in anticipated development plans, strategies and objectives. These and other risk factors that could cause actual results to differ materially from those expressed or implied in our forward-looking statements are and will be discussed in the Company’s filings with the U.S. Securities and Exchange Commission from time to time, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this communication. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

        

Exhibit No.

Description

99.1

 

Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update

99.2

 

Vivani Medical, Inc. slide presentation dated November 12, 2026.

99.3

 

Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document). 

 



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VIVANI MEDICAL, INC.

 

 

 

Date: November 12, 2026

By:

/s/ Donald Dwyer

 

Name:

Donald Dwyer

 

Title:

Chief Business Officer

 



Exhibit 99.1

Graphics

 

Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update

 

Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week

 

Cortigent-ClearOne merger is awaiting final regulatory approvals allowing establishment of Cortigent as a standalone company trading on the Nasdaq under ticker symbol CRGT

 

ALAMEDA, Calif., November 11, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

 

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani” said Adam Mendelsohn, PhD, CEO of the Company. “The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development."

 

Dr. Mendelsohn continued: “Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit. Another key feature afforded by our unique NanoPortal implant technology is the ability to provide an “off-ramp” when discontinuation of therapy is warranted for example when a woman becomes pregnant or there is an aspiration risk during surgery. While there are multiple GLP-1 injectable candidates targeting monthly or quarterly administration under development, none can offer reversibility comparable to our NanoPortal implants. We strongly believe this could be an important consideration for the more than 20% of current GLP-1 users who are women of child-bearing potential.”

 

Recent Business Highlights

 

On October 30, 2026, the Company filed an current report on Form 8-K with the U.S. Securities and Exchange Commission to clarify that the expected close of the of the Cortigent merger remains subject to final regulatory approval and is expected to close shortly after approval is received.

 

On August 6, 2026, Vivani announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to twelve-months of continuous drug delivery utilizing our proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight were measured. Top-Line results from the SLIM-1 trial are anticipated to be announced later this week.

 

On July 7, 2026, the Company announced the signing of a new agreement with Novo Nordisk, now known as Novo, to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139 is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology associated with this agreement.

 

On July 2, 2026, Vivani announced that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly owned subsidiary Cortigent Inc., ClearOne, Inc., a Nasdaq-listed company, and a wholly owned subsidiary of ClearOne (“MergerSub”), pursuant to which Cortigent will become a wholly owned subsidiary of ClearOne upon consummation. In connection with the transaction, ClearOne is pursuing a financing which aims to raise $10 million to $15 million concurrently with the merger’s closing.

 

Upcoming Anticipated Milestones

 

Release of top-line data for SLIM-1, the on-going Phase 1 study of low-dose NPM-139, Vivani’s miniature, ultra long-acting semaglutide implant under development for chronic weight management, are anticipated in November 2026.

 

Preparation, and submission of an Investigational New Drug (“IND”) Application for NPM-139 to support initiation of a proposed Phase 2 dose-ranging study of this semaglutide implant is planned for 2027.

 

The transition of Cortigent into an independent, publicly traded company shortly after receiving final regulatory approval and completion of all closing and related financing activities.

 



Third Quarter 2026 Financial Results

Cash: As of September 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $15.5 million, compared to $20.8 million as of June 30, 2026.

 

Research and development expense, net: Research and development expense, net of grants, during the three months ended September 30, 2026 was $5.0 million, compared to $4.5 million during the three months ended September 30, 2025. The increase of $0.5 million, or 11%, was primarily attributable to an increase in the clinical trial related expense from our Biopharm Division.

 

General and administrative expense, net: General and administrative expense, net of grants, during the three months ended September 30, 2026 was $2.5 million, compared to $2.2 million during the three months ended September 30, 2025. The increase of $0.3 million, or 14%, was primarily attributable to an increase in personnel and related expenses from our Neurostimulation Division and our Biopharm Division.

 

Other income, net: Other income, net during the three months ended September 30, 2026 was $0.3 million, compared to $0.2 million during the three months ended September 30, 2025. The increase of $0.1 million was primarily attributable to amounts recognized under the Australian R&D Tax Incentive Program and higher interest income earned during the period.

 

Net loss: For the foregoing reasons, we had a net loss of $7.3 million during the three months ended September 30, 2026 compared to $6.5 million during the three months ended September 30, 2025.

 

About SLIM-1™ Trial

 

SLIM-1 is an open-label, active-controlled trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) given to 10 participants, over a four-week duration. The trial was designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Changes in weight were also measured. Top-line results from SLIM-1 are anticipated to be released later this week.

 

About Vivani Medical, Inc.

 

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

 

About Cortigent, Inc.

 

Cortigent, Inc., a wholly owned subsidiary of Vivani, is developing brain implant devices to help patients recover critical body functions. Its patent-protected precision neurostimulation technology platform leverages neuroscience and proprietary microelectronics to create advanced medical devices. Vivani’s predecessor, Second Sight Medical Products, previously marketed Argus® II, the first and only medical device to obtain FDA approval to treat a rare form of blindness. This innovative device has helped hundreds of profoundly blind patients to achieve meaningful visual perception. Cortigent’s next generation investigational system, the Orion® cortical stimulation system, has been designed to treat blindness caused by common conditions including glaucoma and diabetic retinopathy. Orion has an FDA Breakthrough Device designation, completed a 6-year Early Feasibility Study in 2025 with promising safety and efficacy results and is covered by an extensive intellectual property estate. Cortigent is also applying its core technology to improving recovery of arm and hand motion in patients with paralysis due to stroke. For more information and patient videos, please visit: www.cortigent.com.

 



Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway, and the closing of the Cortigent merger. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on August 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:

Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

 

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462



 VIVANI MEDICAL, INC.

AND SUBSIDIARIES

 

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except per share data)

 

 

September 30,

 

December 31,

 

 

2026

 

2025

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

$

14,591

 

$

16,232

 

R&D tax credit incentive receivable

 

305

 

 

654

 

Prepaid expenses and other current assets

 

937

 

 

1,012

 

Total current assets

 

15,833

 

 

17,898

 

Property and equipment, net

 

2,763

 

 

2,879

 

Operating lease right-of-use assets, net

 

15,713

 

 

17,230

 

Restricted cash

 

892

 

 

1,338

 

Deposits and other assets

 

109

 

 

48

 

TOTAL ASSETS

$

35,310

 

$

39,393

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Accounts payable

$

1,210

 

$

1,032

 

Accrued expenses

 

1,361

 

 

1,736

 

Litigation accrual

 

1,790

 

 

1,675

 

Accrued compensation expense

 

319

 

 

365

 

Lease liability, current portion

 

1,905

 

 

1,794

 

Total current liabilities

 

6,585

 

 

6,602

 

Lease liability, noncurrent portion

 

15,507

 

 

17,061

 

TOTAL LIABILITIES

 

22,092

 

 

23,663

 

Commitments and contingencies (Note 12)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 0 and 76,428 at September 30, 2026 and December 31, 2025, respectively

 

9

 

 

8

 

Additional paid-in capital

 

182,110

 

 

164,225

 

Accumulated other comprehensive income

 

32

 

 

30

 

Accumulated deficit

 

(168,933)

 

 

(148,533)

 

TOTAL STOCKHOLDERS' EQUITY 

 

13,218

 

 

15,730

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

35,310

 

$

39,393

 

 



VIVANI MEDICAL, INC.

AND SUBSIDIARIES

 

Condensed Consolidated Statements of Operations (Unaudited)

(In thousands, except per share data)

 

 

 Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development, net of grants

$

5,021

 

$

4,519

 

$

13,978

 

$

13,496

 

General and administrative, net of grants

 

2,511

 

 

2,206

 

 

7,375

 

 

7,250

 

Total operating expenses

 

7,532

 

 

6,725

 

 

21,353

 

 

20,746

 

Loss from operations

 

(7,532)

 

 

(6,725)

 

 

(21,353)

 

 

(20,746)

 

Other income, net

 

282

 

 

195

 

 

953

 

 

770

 

Net loss

$

(7,250)

 

$

(6,530)

 

$

(20,400)

 

$

(19,976)

 

Net loss per common share - basic and diluted

$

(0.08)

 

$

(0.11)

 

$

(0.24)

 

$

(0.34)

 

Weighted average common shares outstanding - basic and diluted

 

90,119

 

 

59,711

 

 

86,192

 

 

59,399

 

 



Exhibit 99.2

Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics

 



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics



Exhibit 99.3

Graphics

 

Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects

 

Strong NPM-139 safety and tolerability profile:

-0 of 10 NPM-139 subjects experienced adverse events reported as treatment related

-5 of 10 Wegovy subjects (control group) experienced adverse events reported as treatment related (gastrointestinal only, consistent with marketed GLP-1 therapies)

 

Encouraging NPM-139 semaglutide release profile:

-No NPM-139 rapid drug exposure increases; maximum drug levels from a single administration measured at ~16 days (versus ~2.4 days for the Wegovy control group)

-NPM-139 semaglutide delivery was encouraging and consistent with preclinical performance

-Comparable weight loss was observed between the NPM-139 and Wegovy groups

 

Clinical advancement supported:

-Vivani will advance NPM-139 towards a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027

-Vivani will explore the potential for clinical development of NPM-139 in GLP-1-naïve patients based on the positive SLIM-1 tolerability profile

 

ALAMEDA, Calif., November 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported positive top-line results from SLIM-1, the Company’s recently completed Phase 1 trial of low-dose NPM-139 (semaglutide implant) and a control group of low-dose Wegovy™ (semaglutide injection). NPM-139 is a subdermal implant being designed for once or twice-yearly administration under development for chronic weight management in obese or overweight patients.

 

“The positive top-line data from our SLIM-1 Phase 1 trial marks a critical milestone for Vivani, demonstrating encouraging clinical translation from preclinical models to humans, an encouraging delivery profile, and a strong tolerability profile,” said Adam Mendelsohn, CEO of Vivani Medical. “Real-world data show a staggering level of GLP-1 therapy dropoff. By some estimates, more than 50% of GLP-1 users discontinue their therapy within a single year, with gastrointestinal side effects driving much of this attrition. The long-term health outcomes and related pharmacoeconomic value that have been associated with GLP-1 therapy are only realized when patients remain on treatment for durations significantly longer than one year. The absence of rapid drug exposure increases from the NPM-139 group is both desirable and reassuring because rapid increases in drug concentrations have been associated with tolerability issues with other GLP-1 therapies. The strong NPM-139 safety and tolerability profile in SLIM-1 reinforces our belief that NPM-139 may directly address a major reason for attrition in GLP-1 therapies, while simultaneously improving medication adherence and convenience for patients.”

 

 



Dr. Mendelsohn continued, “We don’t know of any other company that is developing miniature, ultra-long-acting, GLP-1 implants that make possible a once- or twice-yearly administration frequency, with the reversibility speed of a weekly injection. We expect that quick reversibility will be a compelling feature for certain segments of the GLP-1 market who would like an ultra-long-acting option but would need one that offers quick reversibility, including the approximately 23% of GLP-1 users who are women of child-bearing age due to recommendations against continued GLP-1 use during pregnancy.”

 

Vivani Chairman of the Board, Gregg Williams, stated, “I’m very excited about the new top-line SLIM-1 data released today and continue to believe these miniature, ultra-long-acting drug implants have the potential to revolutionize the treatment of chronic diseases including obesity and type 2 diabetes. I remain committed to supporting the development of Vivani’s portfolio of innovative drug implants and the ultimate benefits these new therapeutic options may deliver to prescribers and their patients.”

 

About SLIM-1™

 

SLIM-1 is an open-label, active-controlled clinical trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) given to a control group of 10 participants, over a four-week duration. The trial was designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Changes in weight were also measured.

 

SLIM-1 was conducted in a single study center in Australia. Implant insertions and removals were brief and successfully completed without any complications. The Wegovy group experienced weight loss of 0.82 percent and the NPM-139 group experienced weight loss of 0.79 percent. No serious adverse events (AEs) were reported in the study.

 

Vivani continues to support Novo Nordisk’s evaluation of NPM-139 and the NanoPortal technology under the non-exclusive agreement announced in July 2026.

 

About Vivani Medical, Inc.

 

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.

 



Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the safety, tolerability, therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:

Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

 

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462


 

Filing Exhibits & Attachments

8 documents

Keep reading